CAR T cell therapy for multiple myeloma: Where are we now and where are we headed? Journal Article
| Authors: | Ghosh, A.; Mailankody, S.; Giralt, S. A.; Landgren, C. O.; Smith, E. L.; Brentjens, R. J. |
| Article Title: | CAR T cell therapy for multiple myeloma: Where are we now and where are we headed? |
| Abstract: | While recent progress has been made in the management of multiple myeloma, it remains a highly fatal malignancy especially among patients with relapsed-refractory disease. Immunotherapy with adoptive T cells targeting myeloma-associated antigens are at various stages of development and have brought about a new hope for cure. This is a review on the emerging field of adoptively transferred engineered T cell based approaches, with an in-depth focus on chimeric antigen receptors (CAR) targeting multiple myeloma. The recent results from CAR T cells targeting B cell maturation antigen are encouraging but eventual resistance to the CAR T cell therapies remain problematic. With newer approaches in therapies for multiple myeloma, the role of transplantation is evolved to form a platform for T cell therapies. © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | multiple myeloma; immunotherapy; tcr; hematopoietic cell transplantation; chimeric antigen receptors; car; bcma |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 59 |
| Issue: | 9 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2018-01-01 |
| Start Page: | 2056 |
| End Page: | 2067 |
| Language: | English |
| DOI: | 10.1080/10428194.2017.1393668 |
| PROVIDER: | scopus |
| PMCID: | PMC5936668 |
| PUBMED: | 29105517 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 4 September 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work